Achieve Life Sciences, Inc.
ACHV· Nasdaq
ACHVAchieve Life Sciences, Inc.
Filed Mar 11, 2025 · 10-K · 70 days after period end · 0000950170-25-036831
derived · Computed from the longer spans the company filed.
| Metric | Q4 2024dderived from reported figures | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures | Q4 2021 |
|---|---|---|---|---|
| Net Income | -$12.36M | -$5.48M | -$11.23M | -$7.15M |
| EPS Diluted | — | — | — | -$0.76 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Achieve Life Sciences, Inc. · CIK 949858 · Engraved from SEC EDGAR
ended Dec 31, 2024 · filed Mar 11, 2025 · 70 d after period end
